Take this quiz to test your knowledge on the monitoring and management of iron overload in patients with thalassemia.

Phase 2 safety and efficacy data showed fixed-duration linvoseltamab prevented disease progression and produced deep responses in pts w/ high-risk smoldering multiple myeloma.

There are persistent global disparities in access to care for patients with hemophilia, coupled with problems in healthcare infrastructure and research capacity.

Take this quiz to test your knowledge on the NCCN Guidelines® on allo-HCT.

Blinatumomab added to consolidation and maintenance therapy improves survival in adults with high-risk Ph-negative B-ALL.

Adding venetoclax to frontline hypomethylating agents may improve remission rates in patients with higher-risk myelodysplastic syndromes.

Take this quiz to test your knowledge on the ISTH SSC working group’s guidelines on gene therapy for patients with hemophilia.

A 5-year analysis of the GAIA/CLL13 trial evaluates fixed-duration venetoclax combinations for previously untreated CLL.

See some significant FDA hematology drug alert news from the first half of 2026, including Decnupaz, Hympavzi, and Opdivo.

Researchers identified gaps in clinical trials and referral systems that limit equitable access to CAR-T therapy for pediatric B-ALL in Europe.

Twice-daily deferiprone is well tolerated in patients with transfusional iron overload due to thalassemia, sickle cell disease, or other anemias.